阿德福韦酯联合拉米夫定与恩替卡韦单药治疗乙肝肝硬化疗效比较(1)
[摘要] 目的 研究分析阿德福韋酯联合拉米夫定与恩替卡韦单药治疗乙肝肝硬化疗效。 方法 随机选取该院2016年8月—2017年8月收治的100例乙肝肝硬化患者为研究对象。对照组进行恩替卡韦单药治疗，实验组进行阿德福韦酯联合拉米夫定治疗。比较分析实验组与对照组患者的乙肝病毒脱氧核糖核酸(HBV-DNA)转阴率、总胆红素(TBIL)、凝血酶活动度(PTA)、丙氨酸氨基转移酶(ALT)等临床指标。结果 治疗12周后，实验组HBV-DNA转阴例数为36例，对照组HBV-DNA转阴例数为27例。实验组与对照组患者的HBV-DNA转阴率分别为72.0%与54.0%，差异有统计学意义(χ2=9.03，P<0.05)。治疗24周后，实验组HBV-DNA转阴率为94.0%，对照组HBV-DNA转阴率为82.0%，差异有统计学意义(χ2=7.89，P<0.05)。实验组与对照组治疗后的PTA水平分别为(66.32±2.12)%与(69.98±2.02)%，差异有统计学意义(t=3.22，P<0.05)。实验组的总胆红素水平为(83.21±3.44)μmol/L，对照组的总胆红素水平(92.10±4.10)μmol/L，差异有统计学意义(t=5.44，P<0.05)。实验组与对照组患者的丙氨酸氨基转移酶指标分别为(43.10±3.02)U/L与(47.44±3.43)U/L，差异有统计学意义(t=6.43，P<0.05)。结论 拉米夫定联合用阿德福韦酯治疗应用于乙肝肝硬化治疗中临床治疗效果优于恩替卡韦单药治疗，可对患者相关临床症状进行缓解，提高生活质量，具有临床推广的意义。
[关键词] 阿德福韦酯；拉米夫定；恩替卡韦；乙肝肝硬化；临床疗效
[中图分类号] R512 [文献标识码] A [文章编号] 1674-0742(2018)06(b)-0020-03
Comparison of Curative Effect of Adefovir Dipivoxil Combined with Lamivudinevir and Single Drug of Entecavir in Treatment of Hepatitis B Liver Cirrhosis
WEN Zhong-wen
Department of Infectious Disease， Quanzhou Anxi Hospital， Anxi， Fujian Province， 362400 China
[Abstract] Objective To research and analyze the curative effect of adefovir dipivoxil combined with lamivudinevir and single drug of entecavir in treatment of hepatitis B liver cirrhosis. Methods 100 cases of patients with hepatitis B liver cirrhosis admitted and treated in our hospital from August 2016 to August 2017 were random selected， the control group used the single drug of entecavir for treatment， while the experimental group were treated with adefovir dipivoxil combined with lamivudinevir， and the HBV-DNA negative-conversion rate， TBIL， PTA， ALT of the two groups were compared and analyzed. Results After 12-week treatment， the difference in the HBV-DNA negative conversion rate between the experimental group and the control group was statistically significant (36 cases vs 27 cases， 72.0% vs 54.0%)，(χ2=9.03， P<0.05) ， after 24-week treatment， the difference in the HBV-DNA negative-conversion rate between the experimental group and the control group was statistically significant (94.0% vs 82.0%)， (χ2=7.89， P<0.05) ， after treatment， the PTA levels in the experimental group and in the control group were respectively (66.32±2.12)%，(69.98±2.02)%， and the difference was statistically significant (t=3.22， P<0.05) ， and the total bilirubin level in the experimental group and in the control group was respectively (83.21±3.44)μmol/L and (92.10±4.10)μmol/L， and the difference was statistically significant (t=5.44， P<0.05) ， and the alanine aminotransferase levels in the experimental group and in the control group were respectively(43.10±3.02) U/L， (47.44±3.43) U/L， and the differences were statistically significant(t=6.43， P<0.05) . Conclusion The application effect of adefovir dipivoxil combined with lamivudinevir in treatment of Hepatitis B liver cirrhosis is better than that of single drug of entecavir， which can relieve the clinical related symptoms and improve the quality of life， and it is worth clinical promotion., 百拇医药(温钟文)
[关键词] 阿德福韦酯；拉米夫定；恩替卡韦；乙肝肝硬化；临床疗效
[中图分类号] R512 [文献标识码] A [文章编号] 1674-0742(2018)06(b)-0020-03
Comparison of Curative Effect of Adefovir Dipivoxil Combined with Lamivudinevir and Single Drug of Entecavir in Treatment of Hepatitis B Liver Cirrhosis
WEN Zhong-wen
Department of Infectious Disease， Quanzhou Anxi Hospital， Anxi， Fujian Province， 362400 China
[Abstract] Objective To research and analyze the curative effect of adefovir dipivoxil combined with lamivudinevir and single drug of entecavir in treatment of hepatitis B liver cirrhosis. Methods 100 cases of patients with hepatitis B liver cirrhosis admitted and treated in our hospital from August 2016 to August 2017 were random selected， the control group used the single drug of entecavir for treatment， while the experimental group were treated with adefovir dipivoxil combined with lamivudinevir， and the HBV-DNA negative-conversion rate， TBIL， PTA， ALT of the two groups were compared and analyzed. Results After 12-week treatment， the difference in the HBV-DNA negative conversion rate between the experimental group and the control group was statistically significant (36 cases vs 27 cases， 72.0% vs 54.0%)，(χ2=9.03， P<0.05) ， after 24-week treatment， the difference in the HBV-DNA negative-conversion rate between the experimental group and the control group was statistically significant (94.0% vs 82.0%)， (χ2=7.89， P<0.05) ， after treatment， the PTA levels in the experimental group and in the control group were respectively (66.32±2.12)%，(69.98±2.02)%， and the difference was statistically significant (t=3.22， P<0.05) ， and the total bilirubin level in the experimental group and in the control group was respectively (83.21±3.44)μmol/L and (92.10±4.10)μmol/L， and the difference was statistically significant (t=5.44， P<0.05) ， and the alanine aminotransferase levels in the experimental group and in the control group were respectively(43.10±3.02) U/L， (47.44±3.43) U/L， and the differences were statistically significant(t=6.43， P<0.05) . Conclusion The application effect of adefovir dipivoxil combined with lamivudinevir in treatment of Hepatitis B liver cirrhosis is better than that of single drug of entecavir， which can relieve the clinical related symptoms and improve the quality of life， and it is worth clinical promotion., 百拇医药(温钟文)